G protein-coupled receptors: potential therapeutic targets for diabetic nephropathy

References

• Tang SC. Diabetic nephropathy: a global and growing threat. Hong Kong Med J 2010;16:244–5
   PubMedGoogle Scholar
• Jefferson JA, Shankland SJ, Pichler RH. Proteinuria in diabetic kidney disease: a mechanistic viewpoint. Kidney Int 2008;74:22–36
   PubMed Web of Science ®Google Scholar
• Furukawa M, Gohda T, Tanimoto M, et al. Pathogenesis and novel treatment from the mouse model of type 2 diabetic nephropathy. ScientificWorldJ 2013;2013:928197
   PubMed Web of Science ®Google Scholar
• Wang FL, Tang LQ, Wei W. The connection between GRKs and various signaling pathways involved in diabetic nephropathy. Mol Biol Rep 2012;77:17–26
   Google Scholar
• Jia Z, Sun Y, Liu S, et al. COX-2 but not mPGES-1 contributes to renal PGE2 induction and diabetic proteinuria in mice with type-1 diabetes. PLoS One 2014;9:e93182
   PubMed Web of Science ®Google Scholar
• Tang LQ, Liu S, Zhang ST, et al. Berberine regulates the expression of E-prostanoid receptors in diabetic rats with nephropathy. Mol Biol Rep 2014;41:3339–47
   PubMed Web of Science ®Google Scholar
• Wu D, Peng F, Zhang B, et al. PKC-beta1 mediates glucose-induced Akt activation and TGF-beta1 upregulation in mesangial cells. J Am Soc Nephrol 2009;20:554–66
   PubMed Web of Science ®Google Scholar
• Tominaga T, Abe H, Ueda O, et al. Activation of bone morphogenetic protein 4 signaling leads to glomerulosclerosis that mimics diabetic nephropathy. J Biol Chem 2011;286:20109–16
   PubMed Web of Science ®Google Scholar
• Thibodeau JF, Nasrallah R, Carter A, et al. PTGER1 deletion attenuates renal injury in diabetic mouse models. Am J Pathol 2013;183:1789–802
   PubMed Web of Science ®Google Scholar
• Makino H, Tanaka I, Mukoyama M, et al. Prevention of diabetic nephropathy in rats by prostaglandin E receptor EP1-selective antagonist. J Am Soc Nephrol 2002;1:1757–65
   Web of Science ®Google Scholar
• Yang T, Du Y. Distinct roles of central and peripheral prostaglandin E2 and EP subtypes in blood pressure regulation. Am J Hypertens 2012;25:1042–9
   PubMed Web of Science ®Google Scholar
• Mohamed R, Jayakumar C, Ramesh G. Chronic administration of EP4-selective agonist exacerbates albuminuria and fibrosis of the kidney in streptozotocin-induced diabetic mice through IL-6. Lab Invest 2013;93:933–45
   PubMed Web of Science ®Google Scholar
• Stitt-Cavanagh EM, Faour WH, Takami K, et al. A maladaptive role for EP4 receptors in podocytes. J Am Soc Nephrol 2010;21:1678–90
   PubMed Web of Science ®Google Scholar
• Yang Y, Ni W, Cai M, et al. The renoprotective effects of berberine via the EP4-Gαs-cAMP signaling pathway in different stages of diabetes in rats. J Recept Signal Transduct Res 2014;34:445–55
   PubMed Web of Science ®Google Scholar
• Elsherbiny NM, Al-Gayyar MM. Adenosine receptors: new therapeutic targets for inflammation in diabetic nephropathy. Inflamm Allergy Drug Targets 2013;12:153–61
   PubMedGoogle Scholar
• Quezada C, Alarcon S, Jaramillo C, et al. Targeting adenosine signaling to treatment of diabetic nephropathy. Curr Drug Targets 2013;14:490–6
   PubMed Web of Science ®Google Scholar
• Eisenstein A, Ravid K. G protein-coupled receptors and adipogenesis: a focus on adenosine receptors. J Cell Physiol 2014;229:414–21
   PubMed Web of Science ®Google Scholar
• Cardenas A, Toledo C, Oyarzun C, et al. Adenosine A(2B) receptor-mediated VEGF induction promotes diabetic glomerulopathy. Lab Invest 2013;93:135–44
   PubMed Web of Science ®Google Scholar
• Eremina V, Sood M, Haigh J, et al. Glomerular-specific alterations of VEGF-A expression lead to distinct congenital and acquired renal diseases. J Clin Invest 2003;111:707–16
   PubMed Web of Science ®Google Scholar
• Sison K, Eremina V, Baelde H, et al. Glomerular structure and function require paracrine, not autocrine, VEGF-VEGFR-2 signaling. J Am Soc Nephrol 2010;21:1691–701
   PubMed Web of Science ®Google Scholar
• Schrijvers BF, De Vriese AS, Tilton RG, et al. Inhibition of vascular endothelial growth factor (VEGF) does not affect early renal changes in a rat model of lean type 2 diabetes. Horm Metab Res 2005;37:21–5
   PubMed Web of Science ®Google Scholar
• Lan HY, Chung AC. TGF-beta/Smad signaling in kidney disease. Semin Nephrol 2012;32:236–43
   PubMed Web of Science ®Google Scholar
• Ibrahim AS, El-Shishtawy MM, Zhang W, et al. A((2)A) adenosine receptor (A((2)A)AR) as a therapeutic target in diabetic retinopathy. Am J Pathol 2011;178:2136–45
   PubMed Web of Science ®Google Scholar
• Awad AS, Rouse M, Liu L, et al. Activation of adenosine 2A receptors preserves structure and function of podocytes. J Am Soc Nephrol 2008;19:59–68
   PubMed Web of Science ®Google Scholar
• Vallon V, Schroth J, Satriano J, et al. Adenosine A(1) receptors determine glomerular hyperfiltration and the salt paradox in early streptozotocin diabetes mellitus. Nephron Physiol 2009;111:30–8
   Google Scholar
• Kohan DE. Endothelin, hypertension and chronic kidney disease: new insights. Curr Opin Nephrol Hypertens 2010;19:134–9
   PubMed Web of Science ®Google Scholar
• Lenoir O, Milon M, Virsolvy A, et al. Direct action of endothelin-1 on podocytes promotes diabetic glomerulosclerosis. J Am Soc Nephrol 2014;25:1050–62
   PubMed Web of Science ®Google Scholar
• Horinouchi T, Terada K, Higashi T, Miwa S. Endothelin receptor signaling: new insight into its regulatory mechanisms. J Pharmacol Sci 2013;123:85–101
   PubMed Web of Science ®Google Scholar
• Yang J, Zeng Z, Wu T, et al. Emodin attenuates high glucose-induced TGF-β1 and fibronectin expression in mesangial cells through inhibition of NF-κB pathway. Exp Cell Res 2013;319:3182–9
   PubMed Web of Science ®Google Scholar
• Miura S, Imaizumi S, Saku K. Recent progress in molecular mechanisms of angiotensin II type 1 and 2 receptors. Curr Pharm Des 2013;19:2981–7
   PubMed Web of Science ®Google Scholar
• Zoja C, Cattaneo S, Fiordaliso F, et al. Distinct cardiac and renal effects of ETA receptor antagonist and ACE inhibitor in experimental type 2 diabetes. Am J Physiol Renal Physiol 2011;301:F1114–23
   PubMed Web of Science ®Google Scholar
• Sen S, Chen S, Feng B, et al. Renal, retinal and cardiac changes in type 2 diabetes are attenuated by macitentan, a dual endothelin receptor antagonist. Life Sci 2012;91:658–68
   PubMed Web of Science ®Google Scholar
• Oates PJ. Aldose reductase inhibitors and diabetic kidney disease. Curr Opin Investig Drugs 2010;11:402–17
   PubMed Web of Science ®Google Scholar
• Pfab T, Thone-Reineke C, Theilig F, et al. Diabetic endothelin B receptor-deficient rats develop severe hypertension and progressive renal failure. J Am Soc Nephrol 2006;17:1082–9
   PubMed Web of Science ®Google Scholar
• Ketsawatsomkron P, Stepp DW, Fulton DJ, Marrero MB. Molecular mechanism of angiotensin II-induced insulin resistance in aortic vascular smooth muscle cells: roles of protein tyrosine phosphatase-1B. Vascul Pharmacol 2010;53:160–8
   PubMed Web of Science ®Google Scholar
• Akazawa H, Yano M, Yabumoto C, et al. Angiotensin II type 1 and type 2 receptor-induced cell signaling. Curr Pharm Des 2013;19:2988–95
   PubMed Web of Science ®Google Scholar
• Ni WJ, Tang LQ, Wei W. Research progress in signalling pathway in diabetic nephropathy. Diabetes Metab Res Rev 2015;31:221–33
   PubMed Web of Science ®Google Scholar
• Muller-Fielitz H, Landolt J, Heidbreder M, et al. Improved insulin sensitivity after long-term treatment with AT1 blockers is not associated with PPARγ target gene regulation. Endocrinology 2012;153:1103–15
   PubMed Web of Science ®Google Scholar
• Thangaraju P, Chakrabarti A, Banerjee D, et al. Dual blockade of renin angiotensin system in reducing the early changes of diabetic retinopathy and nephropathy in a diabetic rat model. N Am J Med Sci 2014;6:625–32
   PubMedGoogle Scholar
• Mima A, Kitada M, Geraldes P, et al. Glomerular VEGF resistance induced by PKCδ/SHP-1 activation and contribution to diabetic nephropathy. FASEB J 2012;26:2963–74
   PubMed Web of Science ®Google Scholar
• Koulis C, Chow BS, McKelvey M, et al. AT2R agonist, compound 21, is reno-protective against type 1 diabetic nephropathy. Hypertension 2015;65:1073–81
   PubMed Web of Science ®Google Scholar
• Jenkin KA, Verty AN, McAinch AJ, et al. Endocannabinoids and the renal proximal tubule: an emerging role in diabetic nephropathy. Int J Biochem Cell Biol 2012;44:2028–31
   PubMed Web of Science ®Google Scholar
• Nam DH, Lee MH, Kim JE, et al. Blockade of cannabinoid receptor 1 improves insulin resistance, lipid metabolism, and diabetic nephropathy in db/db mice. Endocrinology 2012;153:1387–96
   PubMed Web of Science ®Google Scholar
• Lim SK, Park SH. The high glucose-induced stimulation of B1R and B2R expression via CB(1)R activation is involved in rat podocyte apoptosis. Life Sci 2012;91:895–906
   PubMed Web of Science ®Google Scholar
• Barutta F, Corbelli A, Mastrocola R, et al. Cannabinoid receptor 1 blockade ameliorates albuminuria in experimental diabetic nephropathy. Diabetes 2010;59:1046–54
   PubMed Web of Science ®Google Scholar
• Barutta F, Grimaldi S, Franco I, et al. Deficiency of cannabinoid receptor of type 2 worsens renal functional and structural abnormalities in streptozotocin-induced diabetic mice. Kidney Int 2014;86:979–90
   PubMed Web of Science ®Google Scholar
• Barutta F, Piscitelli F, Pinach S, et al. Protective role of cannabinoid receptor type 2 in a mouse model of diabetic nephropathy. Diabetes 2011;60:2386–96
   PubMed Web of Science ®Google Scholar
• Puddu A, Mach F, Nencioni A, et al. An emerging role of glucagon-like peptide-1 in preventing advanced-glycation-end-product-mediated damages in diabetes. Mediators Inflamm 2013;2013:591056
   PubMedGoogle Scholar
• Li W, Cui M, Wei Y, et al. Inhibition of the expression of TGF-β1 and CTGF in human mesangial cells by exendin-4, a glucagon-like peptide-1 receptor agonist. Cell Physiol Biochem 2012;30:749–57
   PubMed Web of Science ®Google Scholar
• Xie J, El SN, Qi C, et al. Exendin-4 stimulates islet cell replication via the IGF1 receptor activation of mTORC1/S6K1. J Mol Endocrinol 2014;53:105–15
   PubMed Web of Science ®Google Scholar
• Mima A, Hiraoka-Yamomoto J, Li Q, et al. Protective effects of GLP-1 on glomerular endothelium and its inhibition by PKCβ activation in diabetes. Diabetes 2012;61:2967–79
   PubMed Web of Science ®Google Scholar
• Kodera R, Shikata K, Kataoka HU, et al. Glucagon-like peptide-1 receptor agonist ameliorates renal injury through its anti-inflammatory action without lowering blood glucose level in a rat model of type 1 diabetes. Diabetologia 2011;54:965–78
   PubMed Web of Science ®Google Scholar
• Imasawa T, Kitamura H, Ohkawa R, et al. Unbalanced expression of sphingosine 1-phosphate receptors in diabetic nephropathy. Exp Toxicol Pathol 2010;62:53–60
   PubMed Web of Science ®Google Scholar
• Nam BY, Paeng J, Kim SH, et al. The MCP-1/CCR2 axis in podocytes is involved in apoptosis induced by diabetic conditions. Apoptosis 2012;17:1–13
   PubMed Web of Science ®Google Scholar
• Day RT, Cavaglieri RC, Feliers D. Apelin retards the progression of diabetic nephropathy. Am J Physiol Renal Physiol 2013;304:F788–800
   PubMed Web of Science ®Google Scholar